FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Kirschmeier

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Disorders

Neoplasms

Concepts & Ideas

Procedures

Xenograft Model Antitumor Assays

Co-author Network

Publications

TOP 3
Andrea D Basso; Sara Esposite; Kimberly Gray; Daniel J Hicklin; Angela D Kerekes; Suining Lee; Lianzhu Liang; Ming Liu; Frederick J Monsma; Abdul Ponery; Elizabeth B Smith; Jayaram R Tagat; Seema Tevar; Yushi Xiao; Tao Yu; Yonglian Zhang; Paul Kirschmeier
SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
Andrea D Basso; Ming Liu; Chaoyang Dai; Kimberly Gray; Lissette Nale; Seema Tevar; Suining Lee; Lianzhu Liang; Abdul Ponery; Bohdan Yaremko; Elizabeth Smith; Huadong Tang; Payal R Sheth; M Arshad Siddiqui; Daniel J Hicklin; Paul Kirschmeier
SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.
David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Kirschmeier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Andrea D Basso; Sara Esposite; Kimberly Gray; Daniel J Hicklin; Angela D Kerekes; Suining Lee; Lianzhu Liang; Ming Liu; Frederick J Monsma; Abdul Ponery; Elizabeth B Smith; Jayaram R Tagat; Seema Tevar; Yushi Xiao; Tao Yu; Yonglian Zhang; Paul Kirschmeier
SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
Cancer chemotherapy and pharmacology 2011;68(4):923-33.
2010: Andrea D Basso; Ming Liu; Chaoyang Dai; Kimberly Gray; Lissette Nale; Seema Tevar; Suining Lee; Lianzhu Liang; Abdul Ponery; Bohdan Yaremko; Elizabeth Smith; Huadong Tang; Payal R Sheth; M Arshad Siddiqui; Daniel J Hicklin; Paul Kirschmeier
SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.
Molecular cancer therapeutics 2010;9(11):2993-3002.
2010: David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
Molecular cancer therapeutics 2010;9(8):2344-53.
2010: Vinod R Hegde; Scott Borges; Haiyan Pu; Mahesh Patel; Vincent Gullo; Bonnie Wu; Paul Kirschmeier; Michael J Williams; Vincent Madison; Thierry O Fischmann; Tze-Ming Chan
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.
Bioorganic & medicinal chemistry letters 2010;20(4):1384-7.
2010: Hugh Y Zhu; Alan B Cooper; Jagdish Desai; George Njoroge; Paul Kirschmeier; W Robert Bishop; Corey L Strickland; Alan Hruza; Ronald J Doll; Viyyoor Girijavallabhan
Discovery of C-imidazole azaheptapyridine FPT inhibitors.
Bioorganic & medicinal chemistry letters 2010;20(3):1134-6.
2009: Gongjie Liu; Stacey A Taylor; Cindy H Marrinan; Yunsheng Hsieh; W Robert Bishop; Paul Kirschmeier; Brian J Long
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
International journal of cancer. Journal international du cancer 2009;125(11):2711-20.
2008: Patrick J Roberts; Natalia Y Mitin; Patricia J. Keller; Emily J Chenette; James P Madigan; Rachel O Currin; Adrienne D Cox; Oswald Wilson; Paul Kirschmeier; Channing J Der
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.
The Journal of biological chemistry 2008;283(37):25150-63.
2008: Stacey A Taylor; Cindy H Marrinan; Gongjie Liu; Lissette Nale; W Robert Bishop; Paul Kirschmeier; Ming Liu; Brian J Long
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Gynecologic oncology 2008;109(1):97-106.
2007: Gonjgie Liu; Cindy H Marrinan; Stacey A Taylor; Stuart Black; Andrea D Basso; Paul Kirschmeier; W Robert Bishop; Ming Liu; Brian J Long
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Anti-cancer drugs 2007;18(8):923-31.
2007: Mark W Kieran; Roger J Packer; Arzu Onar; Susan M Blaney; Peter Phillips; Ian F Pollack; J Russell Geyer; Sridharan Gururangan; Anu Banerjee; Stewart Goldman; Christopher D Turner; Jean B Belasco; Alberto Broniscer; Yali Zhu; Emily Frank; Paul Kirschmeier; Paul Statkevich; Antoine Yver; James M Boyett; Larry E Kun
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3137-43.
2007: Sandra Koseoglu; Zhuomei Lu; Chandra Kumar; Paul Kirschmeier; Jun Zou
AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines.
Cancer biology & therapy 2007;6(5):755-62.
2006: Terrill McClanahan; Sandra Koseoglu; Kathleen Smith; Jeffrey Grein; Eric L Gustafson; Stuart Black; Paul Kirschmeier; Ahmed A Samatar
Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors.
Cancer biology & therapy 2006;5(4):419-26.
2006: Andrea D Basso; Paul Kirschmeier; W Robert Bishop
Lipid posttranslational modifications. Farnesyl transferase inhibitors.
Journal of lipid research 2006;47(1):15-31.
2005: Andrea D Basso; Asra Mirza; Gongjie Liu; Brian J Long; W Robert Bishop; Paul Kirschmeier
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
The Journal of biological chemistry 2005;280(35):31101-8.
2005: Qun Wu; Wei Ding; Asra Mirza; Tish Van Arsdale; Iris Wei; W Robert Bishop; Andrea Basso; Terrill McClanahan; Lin Luo; Paul Kirschmeier; Eric L Gustafson; Marco Hernandez; Suxing Liu
Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target.
The Journal of biological chemistry 2005;280(13):12935-43.
2004: F George Njoroge; Bancha Vibulbhan; Xiongwei Shi; Corey L Strickland; Paul Kirschmeier; Robert Bishop; Amin A Nomeir; Viyyoor Girijavallabhan
Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.
Bioorganic & medicinal chemistry letters 2004;14(23):5899-902.
2004: F George Njoroge; Bancha Vibulbhan; Patrick Pinto; Corey L Strickland; Paul Kirschmeier; W Robert Bishop; Viyyoor Girijavallabhan
Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.
Bioorganic & medicinal chemistry letters 2004;14(23):5877-80.
2004: Ronald J Doll; Paul Kirschmeier; W Robert Bishop
Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Current opinion in drug discovery & development 2004;7(4):478-86.
2004: Zhuomei Lu; Zhizhang Yin; Linda James; Rosalinda Syto; Jill M Stafford; Sandra Koseoglu; Todd Mayhood; Joseph Myers; William T Windsor; Paul Kirschmeier; Ahmed A Samatar; Bruce A Malcolm; Tammy C Turek-Etienne; C Chandra Kumar
Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase.
Journal of biomolecular screening 2004;9(4):309-21.
2004: Fadlo R Khuri; Bonnie S Glisson; Edward S Kim; Paul Statkevich; Peter F Thall; Michael L Meyers; Roy S Herbst; Reginald F Munden; Craig Tendler; Yali Zhu; Sandra Bangert; Elizabeth Thompson; Charles Lu; Xue-Mei Wang; Dong M Shin; Merrill S Kies; Vassiliki A Papadimitrakopoulou; Frank V Fossella; Paul Kirschmeier; W Robert Bishop; Waun Ki Hong
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2968-76.
2003: W Robert Bishop; Paul Kirschmeier; Charles Baum
Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation.
Cancer biology & therapy 2003;2(4 Suppl 1):S96-104.
2003: Asra Mirza; Qun Wu; Luquan Wang; Terrill McClanahan; W Robert Bishop; Ferdous Gheyas; Wei Ding; Beth Hutchins; Tish Hockenberry; Paul Kirschmeier; Jonathan R Greene; Suxing Liu
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.
Oncogene 2003;22(23):3645-54.
2003: Charles Baum; Paul Kirschmeier
Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Current oncology reports 2003;5(2):99-107.
2003: Arthur G Taveras; Paul Kirschmeier; Charles M Baum
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Current topics in medicinal chemistry 2003;3(10):1103-14.
2002: Qun Wu; Paul Kirschmeier; Tish Hockenberry; Tong-Yuan Yang; Diana L Brassard; Luquan Wang; Terrill McClanahan; Stuart Black; Giovanni Rizzi; Mary Lynn Musco; Asra Mirza; Suxing Liu
Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells.
The Journal of biological chemistry 2002;277(39):36329-37.
2002: Arthur G Taveras; Cynthia Aki; Jianping Chao; Ronald J Doll; Tarik Lalwani; Viyyoor Girijavallabhan; Corey L Strickland; William T Windsor; Patricia Weber; Frank Hollinger; Mark Snow; Robert Patton; Paul Kirschmeier; Linda James; Ming Liu; Amin A Nomeir
Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.
Journal of medicinal chemistry 2002;45(18):3854-64.
2002: Asra Mirza; Marnie McGuirk; Tish Hockenberry; Qun Wu; Hena Ashar; Stuart Black; Shu Fen Wen; Luquan Wang; Paul Kirschmeier; W Robert Bishop; Loretta L Nielsen; Cecil B Pickett; Suxing Liu
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
Oncogene 2002;21(17):2613-22.
2002: Alan B Cooper; Corey L Strickland; James Wang; Jagdish Desai; Paul Kirschmeier; Robert Patton; W Robert Bishop; Patricia C Weber; Viyyoor Girijavallabhan
Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.
Bioorganic & medicinal chemistry letters 2002;12(4):601-5.
2002: Diana L Brassard; Jessie M English; Michael Malkowski; Paul Kirschmeier; TL Nagabhushan; W Robert Bishop
Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Experimental cell research 2002;273(2):138-46.
2001: Luquan Wang; Qun Wu; Ping Qiu; Asra Mirza; Marnie McGuirk; Paul Kirschmeier; Jonathan R Greene; Y Wang; Cecil B Pickett; Suxing Liu
Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches.
The Journal of biological chemistry 2001;276(47):43604-10.
2001: D G Peters; Russell R Hoover; Melissa Gerlach; Eugene Koh; H Zhang; K Choe; Paul Kirschmeier; W Robert Bishop; George Q Daley
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Blood 2001;97(5):1404-12.
2001: Ming Liu; W Robert Bishop; Loretta L Nielsen; Matthew Bryant; Paul Kirschmeier
Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models.
Methods in enzymology 2001;333():306-18.
2001: Paul Kirschmeier; D Whyte; O Wilson; W Robert Bishop; J K Pai
In vivo prenylation analysis of Ras and Rho proteins.
Methods in enzymology 2001;332():115-27.
2001: Hena Ashar; Linda James; K Gray; Donna Carr; Marnie McGuirk; Eugene Maxwell; Stuart Black; L Armstrong; Ronald J Doll; Arthur G Taveras; W Robert Bishop; Paul Kirschmeier
The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Experimental cell research 2001;262(1):17-27.
2000: Hena Ashar; L Armstrong; L J James; D M Carr; K Gray; Arthur G Taveras; Ronald J Doll; W Robert Bishop; Paul Kirschmeier
Biological effects and mechanism of action of farnesyl transferase inhibitors.
Chemical research in toxicology 2000;13(10):949-52.
2000: Hena Ashar; Linda James; K Gray; Donna Carr; Stuart Black; L Armstrong; W Robert Bishop; Paul Kirschmeier
Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.
The Journal of biological chemistry 2000;275(39):30451-7.
2000: Alex A. Adjei; Charles Erlichman; JN Davis; David L Cutler; Jeff A Sloan; Randolph S Marks; Lorelei J Hanson; Phyllis A Svingen; Pamela J Atherton; W Robert Bishop; Paul Kirschmeier; Scott H Kaufmann
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Cancer research 2000;60(7):1871-7.
1999: Arthur G Taveras; J Deskus; Jianping Chao; C J Vaccaro; F George Njoroge; Bancha Vibulbhan; Patrick Pinto; SW Remiszewski; JD del Rosario; Ronald J Doll; C Alvarez; T Lalwani; AK Mallams; RR Rossman; A Afonso; Viyyoor Girijavallabhan; Ashit K Ganguly; Birendra Pramanik; Larry Heimark; W Robert Bishop; Luquan Wang; Paul Kirschmeier; Linda James; Donna Carr; Ming Liu
Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.
Journal of medicinal chemistry 1999;42(14):2651-61.
1999: F George Njoroge; Bancha Vibulbhan; W Robert Bishop; Paul Kirschmeier; Matthew Bryant; Amin A Nomeir; Ming Liu; Ronald J Doll; Viyyoor Girijavallabhan; Ashit K Ganguly
Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity.
Bioorganic & medicinal chemistry 1999;7(5):861-7.
1999: Ming Liu; Matthew Bryant; J Chen; S Lee; B Yaremko; Z Li; J Dell; Philip Lipari; Michael Malkowski; N Prioli; RR Rossman; Walter A Korfmacher; Amin A Nomeir; Chin-Chung Lin; AK Mallams; Ronald J Doll; JJ Catino; Viyyoor Girijavallabhan; Paul Kirschmeier; W Robert Bishop
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Cancer chemotherapy and pharmacology 1999;43(1):50-8.
1998: F George Njoroge; Arthur G Taveras; Joseph Kelly; SW Remiszewski; AK Mallams; Ronald L Wolin; A Afonso; Alan B Cooper; DF Rane; Yi-Tsung Liu; J Wong; Bancha Vibulbhan; Patrick Pinto; J Deskus; CS Alvarez; JD del Rosario; M Connolly; J Wang; J Desai; RR Rossman; W Robert Bishop; Robert Patton; Luquan Wang; Paul Kirschmeier; Ashit K Ganguly
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
Journal of medicinal chemistry 1998;41(24):4890-902.
1998: Ashit K Ganguly; Yu-Sen Wang; Birendra Pramanik; Ronald J Doll; ME Snow; Arthur G Taveras; SW Remiszewski; D Cesarz; JD del Rosario; Bancha Vibulbhan; JE Brown; Paul Kirschmeier; EC Huang; Larry Heimark; ANTHONY TSARBOPOULOS; Viyyoor Girijavallabhan; Robert M Aust; Edward L Brown; DM DeLisle; Shella A Fuhrman; Thomas F Hendrickson; Charles R Kissinger; Robert A Love; Wes Sisson; Stephen E Webber
Interaction of a novel GDP exchange inhibitor with the Ras protein.
Biochemistry 1998;37(45):15631-7.
1998: Ronald L Wolin; M Connolly; Joseph Kelly; J Weinstein; Stuart B Rosenblum; A Afonso; Linda James; Paul Kirschmeier; W Robert Bishop
Inhibitors of farnesyl protein transferase. Synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system.
Bioorganic & medicinal chemistry letters 1998;8(18):2521-6.
1998: AK Mallams; RR Rossman; Ronald J Doll; Viyyoor Girijavallabhan; Ashit K Ganguly; J Petrin; Luquan Wang; Robert Patton; W Robert Bishop; D M Carr; Paul Kirschmeier; JJ Catino; Matthew Bryant; KJ Chen; Walter A Korfmacher; Cymbylene Nardo; Shiyong Wang; Amin A Nomeir; Chin-Chung Lin; Z Li; J Chen; S Lee; J Dell; Philip Lipari; Ming Liu
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.
Journal of medicinal chemistry 1998;41(6):877-93.
1997: D B Whyte; Paul Kirschmeier; Tish Hockenberry; I Nunez-Oliva; Linda James; JJ Catino; W Robert Bishop; J K Pai
K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.
The Journal of biological chemistry 1997;272(22):14459-64.
1997: Ashit K Ganguly; Birendra Pramanik; EC Huang; S Liberles; Larry Heimark; Yan-Hui Liu; ANTHONY TSARBOPOULOS; Ronald J Doll; Arthur G Taveras; SW Remiszewski; ME Snow; Yu-Sen Wang; Bancha Vibulbhan; D Cesarz; JE Brown; JD del Rosario; Linda James; Paul Kirschmeier; Viyyoor Girijavallabhan
Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry.
Bioorganic & medicinal chemistry 1997;5(5):817-20.
1997: Fang L Zhang; Paul Kirschmeier; Donna Carr; Linda James; R W Bond; Luquan Wang; Robert Patton; William T Windsor; Rosalinda Syto; Rumin Zhang; W Robert Bishop
Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I.
The Journal of biological chemistry 1997;272(15):10232-9.
1997: Arthur G Taveras; SW Remiszewski; Ronald J Doll; D Cesarz; EC Huang; Paul Kirschmeier; Birendra Pramanik; ME Snow; Yu-Sen Wang; JD del Rosario; Bancha Vibulbhan; B B Bauer; JE Brown; Donna Carr; JJ Catino; C A Evans; Viyyoor Girijavallabhan; Larry Heimark; Linda James; S Liberles; C Nash; L Perkins; Mary M Senior; ANTHONY TSARBOPOULOS; Stephen E Webber
Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.
Bioorganic & medicinal chemistry 1997;5(1):125-33.
1997: F George Njoroge; Ronald J Doll; Bancha Vibulbhan; CS Alvarez; W Robert Bishop; J Petrin; Paul Kirschmeier; Nicholas I Carruthers; JK Wong; M M Albanese; John J Piwinski; JJ Catino; Viyyoor Girijavallabhan; Ashit K Ganguly
Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.
Bioorganic & medicinal chemistry 1997;5(1):101-13.
1997: AK Mallams; F George Njoroge; Ronald J Doll; ME Snow; James J Kaminski; RR Rossman; Bancha Vibulbhan; W Robert Bishop; Paul Kirschmeier; Ming Liu; Matthew Bryant; C Alvarez; Donna Carr; Linda James; I King; Z Li; Chin-Chung Lin; Cymbylene Nardo; J Petrin; SW Remiszewski; Arthur G Taveras; Shiyong Wang; J Wong; JJ Catino; Ashit K Ganguly
Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.
Bioorganic & medicinal chemistry 1997;5(1):93-9.
1996: Yu-Sen Wang; A F Frederick; M M Senior; B A Lyons; S Black; Paul Kirschmeier; L M Perkins; O Wilson
Chemical shift assignments and secondary structure of the Grb2 SH2 domain by heteronuclear NMR spectroscopy.
Journal of biomolecular NMR 1996;7(2):89-98.
1991: S R Hubbard; W R Bishop; Paul Kirschmeier; S J George; S P Cramer; W A Hendrickson
Identification and characterization of zinc binding sites in protein kinase C.
Science (New York, N.Y.) 1991;254(5039):1776-9.